EuroPCR 2024 | SOLVE-TAVI: Self Expanding or Balloon Expandable Valves?

This was a randomized study with 447 patients carried out to compare the 5-year evolution of TAVR using Evolut R and SAPIEN 3, as well as general anesthesia vs. conscious sedation. 

EuroPCR 2024

Randomization was in two stages: first valve selection and later the anesthesia technique, that is, conscious sedation vs general anesthesia.

The populations were similar.

Primary end point included all cause death, stroke, moderate regurgitation to severe, and the need for pacemaker implantation at 5 years. 

Five year outcomes did not show significant differences in primary outcomes (67.7% vs. 63.4%, p=0.34) between patients treated with Evolut R and SAPIEN 3, neither in all-cause mortality (48.5% vs. 47.6%), moderate to severe paravalvular leak (9% vs. 5.8%), or need for pacemaker implantation (29.6% vs. 22.8%). 

Read also: Catheter-Based Therapy for Pulmonary Embolism: Lower Mortality and Rehospitalization?

However, there was higher incidence of stroke in the group treated with SAPIEN 3 (4.8% vs. 0.5%, p=0.001). Also, there were no significant differences in primary end point when looking at the anesthesia technique, or events separately.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Impact of valve type and anesthesia strategy for TAVI – 5-year results of the SOLVE-TAVI Trial.

Reference: Hans Josef Feistritzer.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

TCT 2024 – EVOLVED trial: Early Intervention for Patients with Severe Asymptomatic Aortic Stenosis and Myocardial Fibrosis?

Treating symptomatic severe aortic stenosis (AS) with aortic valve replacement is currently considered a class I recommendation, evidence level B, according to the current...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...